Home | Welcome to Contract Pharma   
Last Updated Saturday, May 25 2013
Print

Financial Reports

Related Searches:

Filter by:

Financial Report: West Pharmaceutical Services
February 16, 2012
Contract manufacturing revenues account for 79% of 4Q11 sales   Read More »
Financial Report: Teva
February 15, 2012
Cephalon sales boost revenues but impact earnings   Read More »
Financial Report: Charles River Laboratories
February 14, 2012
RMS segment sales were up, while PCS segment sales declined   Read More »
Financial Report: BASi
February 10, 2012
Revenues drop 7%   Read More »
Financial Report: Elan
February 8, 2012
Tysabri sales were up 23% in 2011   Read More »
Financial Report: Sanofi
February 8, 2012
Genzyme revenues, growth offset generic impact on flagship products   Read More »
Financial Report: GlaxoSmithKline
February 7, 2012
Vaccines sales drop 19% in 2011   Read More »
Financial Report: Jubilant Life Sciences
February 6, 2012
Revenue in the quarter up 25%, but earnings fall on INR-USD currency movement   Read More »
Financial Report: Gilead Sciences
February 3, 2012
Revenues up 10% in the quarter   Read More »
Financial Report: AstraZeneca
February 2, 2012
Loss of nearly $2 billion in 2011 from generic competition, 7,300 more layoffs to come   Read More »
Financial Report: Biogen Idec
January 31, 2012
In-market Tysabri sales up 23% in 2011   Read More »
Financial Report: Lilly
January 31, 2012
Zyprexa, Gemzar patent losses impact results   Read More »
Financial Report: Pfizer
January 31, 2012
Lipitor losses hit 4Q results   Read More »
Financial Report: Covance
January 27, 2012
Early and late-stage FY revenues up 11% and 7%, respectively   Read More »
Financial Report: Amgen
January 27, 2012
Earnings down 20% in 2011   Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: